Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DCAR-001
- Development stage
- Preclinical
- Lead developer
- Pinion Immunotherapeutics
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
01
Overview
DCAR-001 is an investigational mRNA-based immunotherapy being developed by Pinion Immunotherapeutics for the treatment of acute myeloid leukemia (AML). Developed using Pinion's proprietary AI-driven mRNA platform, DCAR-001 is designed to activate CD8+ cytotoxic T lymphocytes and induce a targeted immune response against AML-associated antigens. The therapeutic candidate utilizes an engineered lipid nanoparticle (LNP) delivery system optimized for lymph node trafficking, antigen-presenting cell (APC) uptake, and major histocompatibility complex class I (MHC-I) loading. DCAR-001 is currently in preclinical development.
Beyond the preview
Go deeper on DCAR-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DCAR-001.